methylamino-phenylalanyl-leucyl-hydroxamic acid

Methylamino-phenylalanyl-leucyl-hydroxamic acid is an experimental small molecule inhibitor primarily studied for its ability to inhibit matrix metalloproteinases, specifically neutrophil collagenase (MMP8) and interstitial collagenase (MMP1)[1][6]. It acts as a hydroxamic acid-based inhibitor, binding to the active site of these enzymes and blocking their proteolytic activity. Preclinical studies have demonstrated its antitumor efficacy in various cancer cell lines, including ovarian, breast, and cervical cancers, where it induces apoptosis and cell cycle arrest—effects attributed to histone deacetylase (HDAC) inhibition[2]. The compound has not been approved for clinical use in any country and remains at the experimental stage.

Other names

(2R)-N'-hydroxy-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide3-BMMHMHHAP